All posts by medical

Dine In Maine: Listen to these podcasts while you prep – Press Herald

Its easier to destroy a pair of headphones than you might think. How do I know? Messy, hard-earned experience.

One pair sliced cleanly into three pieces as I bisected a stubborn butternut squash. The next dangled, then tangled into the ball whisk of my Kitchen Aid as it launched lashings of chocolate buttercream across my kitchen.

Eventually, I caved and bought a Bluetooth speaker. It was either that or give up listening to food podcasts as I cook, and that felt like a bridge too far.

For me, podcasts about the culinary world breed a sense of connection to other home cooks, as well as chefs and restaurateurs, growers and producers. They reinforce the context that frames what I do with my hands as I assemble the components of a dish.

Theyve also introduced me to stories and ideas I might never have sought out on my own. Everything from how to preserve unused cookie dough (freeze it into logs), to the separated-at-birth melodrama of Zinfandel and Primitivo (They took a DNA test; turns out theyre 100% the same grape.)

Whether youre new to food podcasts or a veteran listener, I hope youll find something appetizing in this list of eight of my favorites. Some began airing this year, others have archives several hundred episodes deep, but every one would be worth sacrificing a pair of headphones.

Note: There are many ways to access podcasts. Apps like Spotify, SoundCloud, Apple Podcasts and Stitcher all make locating episodes simple. Many home audio devices, like Amazons Echo (Alexa) and Google Home, also allow access through simple voice requests.

Gastropod

Since 2014, celebrated writers Nicola Twilley and Cynthia Graber have explored the hidden stories behind how (and what) we eat. Each episode takes a single topic caffeine, artificial flavorings, the cherry tomato and refracts it through the overlapping lenses of culture, science and history. Meticulously researched and always entertaining, Gastropod uses the low-key charm of its hosts to sneak up on you. Before you know it, youll be captivated (and peckish).

Quintessential episode: Museums and the Mafia: The Secret History of Citrus (Season 4)

Gastropod.com

The Splendid Table

What began as a nationally syndicated Minnesota Public Radio program aimed at an audience of home cooks, The Splendid Table has, over 21 years, mutated into the leviathan of food podcasts. In no small part, thats due to its early embrace of technology. Splendid Table was one of the first programs to host its own website (starting with featured recipes, then a dinner-themed newsletter and, eventually, full episodes of the show). Some of its popularity is undoubtedly also due to the expertise and charisma of its hosts, Lynne Rossetto Kasper and, since 2017, Francis Lam. With more than 700 episodes in its catalog, theres enough compelling audio content here to keep you busy for months.

Quintessential episodes: Any of the often hilarious annual Turkey Confidential call-in programs. The shows website describes the first in this series (2006) as Thanksgiving triage at its best.

splendidtable.org

The Sporkful

Host Dan Pashmans podcast began as a cross between entertainment and therapy: a release valve for him to process his most obsessive culinary thoughts. Indeed, in 2010, he began The Sporkful with an entire episode parsing the differences between panini and grilled cheese, then moved on to programs about calculating ideal ratios of butter and salt for popcorn, and even tactical planning for dinner at a buffet. In recent years, Pashman has turned The Sporkful into a more interview-oriented podcast, but it has lost none of its original appeal.

Quintessential episode: Episode 19, in which Pashman and NPR science correspondent Robert Krulwich use physics and geometry to optimize sandwich construction and consumption.

sporkful.com

Eaters Digest

Originally birthed in 2015 as Eater Upsell, a podcast primarily about well-known North American chefs, writers and television personalities, this podcast hit an inflection point in 2017, right around the time the restaurant world recognized it had a Mario Batali-shaped #MeToo problem. Since then, and especially under the aegis of current hosts Amanda Kludt and Daniel Geneen, Eaters Digest has branched out to explore the forces that shape the ways we eat out (and, often, in). If you want to find out whats happening right now in the world of food, this should be your first stop.

Quintessential episode: Ruth Reichl and the Rise and Fall of Gourmet Magazine (March 20, 2019).

eater.com/eatersdigest

Cooking Issues

Descriptions can be deceiving. When I first came across Cooking Issues in 2010, I thought it was just another call-in show designed to help home cooks figure out how to roast a squash or debone a duck. I quickly recalibrated my expectations when I heard hosts Dave Arnold and Nastassia Lopez delivering their rapid-fire, stream-of-consciousness advice and discovered the programs orientation toward science and modernist techniques. That doesnt mean you cant listen to find out how to use a bread machine, but a week later, you might wind up learning about avant-garde gastronomic approaches like dispersing aromas with a vape pen or attaching electrodes to food to initiate ohmic heating.

Quintessential episode: Episode 215 (July 21, 2015) featuring legendary author and fellow food-as-science scholar Harold McGee.

heritageradionetwork.org

Home Cooking

When I read last month that Samin Nosrat author of the James Beard Foundation award-winning Salt, Fat, Acid, Heat and host of the Netflix miniseries of the same name and Song Exploder podcast creator HrishikeshHirway were combining forces to host a podcast about cooking during the current pandemic, I subscribed without listening to a single episode. Both bring an easygoing expertise to interviewing guests, like baker Stella Parks and actor/latke aficionado Josh Malina, and offer clear, adaptable answers to listener questions about whether to soak beans and how to make bread when flour is scarce.

Quintessential episode: Home Cookings debut (March 27, 2020) Bean There, Done That and its quick, three-sentence how-to-cook-a-bean recipe.

homecooking.show

Food Court with Richard Blais

Another newcomer, this podcast is unique among its peers because of its game show format. Hosted by Atlanta chef Richard Blais, a former Top Chef: All-Stars champ, Food Court is a rollicking hybrid: part trivia quiz, part debate-based panel show. Each episode features entertaining guest contestants who argue on either side of some of the most contentious culinary issues pie vs. cake, cheap vs. expensive coffee, and most controversial of all: cilantro, yes or no? (For the record, the answer is yes.)

Quintessential episode: Bagels: Toasted vs. Not Toasted (April 7, 2020)

ihr.fm

The Food Coma Podcast with Joe Ricchio

Freelance food writer and former food editor for Down East Magazine, Joe Ricchio is an absolute blast to listen to as he hosts this mostly Maine-focused podcast. Long a fixture of the Portland-area food scene, Ricchio radiates an infectious enthusiasm for his culinary-world guests and their work. Episodes begin with a broad theme (food entertainment, human behavior) but quickly detour into tangents that are at once engaging, revealing and frequently side-splittingly funny.

Quintessential episodes: Relationships with Nellie Edwards (January 27, 2020), wherein Ricchio tells you what he really thinks of using Groupon discounts at restaurants, and Network TV, Motorcycles, and Vulcans with Rob Caldwell (January 6, 2020), a Freaky Friday episode that turns interviewee into interviewer.

foodcomapodcast.com

Andrew Ross has written about food and dining in New York and the United Kingdom. He and his work have been featured on Martha Stewart Living Radio and in The New York Times. He is the recipient of three recent Critics Awards from the Maine Press Association.Contact him at: [emailprotected]Twitter: @AndrewRossME

Invalid username/password.

Please check your email to confirm and complete your registration.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.

Previous

Next

Originally posted here:
Dine In Maine: Listen to these podcasts while you prep - Press Herald

Wehner: ‘The human capacity for self-deception is tremendous’ – Henry Herald

Brian Stelter asks Peter Wehner, a veteran of past GOP administrations, about the willingness of Trump supporters to excuse unpresidential behavior. "The human capacity for self-deception is tremendous," Wehner says. And "they feel that they are in an existential fight, an existential struggle, and Trump is on their side."

TownNews.com Content Exchange

TownNews.com Content Exchange

See more here:
Wehner: 'The human capacity for self-deception is tremendous' - Henry Herald

Safe driving dependent on 3 parts: car, road, driver | News, Sports, Jobs – The Adirondack Daily Enterprise

Consumer Reports had an interesting article, asking the question can we save more lives with advances in safety technology that is reshaping the auto industry. CR questions why the highway death toll is still so stubbornly high. Good question.

As the CR article continues, it makes it clear that there are three parts to safety: the car, the road, and the driver.

The cars

We are doing an excellent job using technology to develop crash-avoidance safety features in cars, such as automatic emergency braking, pedestrian detection, forward collision warning and blind spot warning. CR believes that these safety systems should become standard on all models because they save lives. But with every new safety feature there is a corresponding negative side. Drivers may rely too heavily on what they perceive as the ability of the technology to bail them out of trouble.

The promise of self-driving cars is so exciting because the technology could significantly reduce traffic deaths. More than 90% of crashes are linked to driver error, according to National Highway Transportation Safety Administration. In theory, a robot-driven car doesnt fall asleep or get drunk. It doesnt make human mistakes.

The roads

A poorly designed road can escalate a small error into a fatality. Traffic engineers know that a minor change in the sweep of a curve or an unclear road sign can have an impact on safety. For this reason, dozens of cities in the U.S. are completely rethinking road design with safety top of mind.

In the U.S., there are about 12 roadway deaths per 100,000 people per year, according to the World Health Organization. In much of Western Europe, its fewer than five. In Sweden, its less than three. Some communities are changing their street design and traffic laws. In 2014 New York was one of the first cities in the U.S. to adopt the Vision Zero concept, which calls for city planners to rethink everything about roads, bike lanes and pedestrian routes. The goal is to eliminate all vehicle-related deaths.

Speed limits also play a key role in road safety, yet outside of cities, the trend has been to set them higher. During the 1970s energy crisis, the U.S. adopted a nationwide 55 mph limit. Now most states have a speed limit of 65 or 70 mph on highways. Seven states have adopted an 80 mph speed limit on some highways, and the speed limit is 85 mph on a 40-mile stretch of Texas tollway between Austin and San Antonio.

The driver

Motorists have become used to driving faster than the posted speed limit no matter the number, says Russ Martin, director of policy and government relations at the Governors Highway Safety Association. Even though almost everyone recognizes that speeding isnt safe, they do it anyway.

Its no mystery that driver mistakes contribute to highway crashes and injuries. Drunken driving, speeding and failing to wear a seat belt are three major reasons. Sometimes drivers engage in more than one of these risky behaviors at the same time. Each contributes to about 10,000 traffic deaths per year. Human behavior remains the most common contributor to crashes, but its also the hardest to change.

Safety advocates say the solutions are well known. Seat belt use, for example, is higher in states with strong enforcement. States with tougher drunken-driving laws have lower death rates. Most states ban driver texting and the use of handheld devices while driving, but many drivers do it anyway.

Many drivers think they can multitask while operating a car safely. But National Transportation Safety Board research shows thats a myth; humans can focus cognitive attention only on one thing at a time, says Bruce Landsberg, vice chairman of the NTSB. We try to fix human nature here, but thats really hard.

Hard or not, we need to do it.

Today's breaking news and more in your inbox

See the article here:
Safe driving dependent on 3 parts: car, road, driver | News, Sports, Jobs - The Adirondack Daily Enterprise

Ironshore to Present Posters at the 2020 Neuroscience Education Institute Virtual Scientific Poster Session – Yahoo Finance

Ironshore Pharmaceuticals Inc. ("Ironshore"), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder ("ADHD"), today announced it is presenting two posters featuring new analyses of its novel delayed-release and extended-release methylphenidate formulation. These analyses demonstrate that the uniphasic drug delivery system and site of absorption produce a gradual absorption and protracted elimination phase resulting in attenuated peak drug concentration levels across the dosing range and may lead to a dose-dependent duration of effect. The posters are available for download at the Virtual Scientific Poster Session of the Neuroscience Education Institute ("NEI"). This initiative was coordinated in response to the COVID-19 pandemic and is designed to fill the void in the presentation and dissemination of emerging science historically presented during live meetings. The posters will be accessible to NEIs 65,700 members and subscribers at http://nei.global/vsp.

The two poster presentations are:

Model-Based Approach to Establish Predicted Clinical Response of Delayed-Release and Extended-Release Methylphenidate (DR/ER-MPH) for ADHD TreatmentRoberto Gomeni, PhD, Marina Komolova, PhD; Bev Incledon, PhD; Stephen V. Faraone, PhDhttps://www.neiglobal.com/VSP/NEIVSPDetail/tabid/562/args/7/Default.aspx

Site-Specific Colonic Absorption for an Optimized Pharmacokinetic Profile of DR/ER-MPH for the Treatment of ADHDFeng Zhang, PhD; Norberto J. DeSousa, MA; F. Randy Sallee, MD, PhD; David Lickrish; Bev Incledon, PhDhttps://www.neiglobal.com/VSP/NEIVSPDetail/tabid/562/args/6/Default.aspx

The posters will enable NEIs stakeholders to learn more about JORNAY PM (methylphenidate HCl) extended-release capsules CII, which was approved in August 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in patients 6 years and older.

"Ironshore is proud to participate in NEIs innovative new forum to present data that are relevant to psychiatrists, psychiatric nurse practitioners, and other mental health care professionals," said Dr. Randy Sallee, Ironshores Chief Medical Officer. "We look forward to sharing new data related to the unique absorption profile of JORNAY PM facilitated by the DELEXIS delayed-release, extended-release, drug delivery technology as well as an evaluation of the medicines pharmacokinetic profile, after single 20mg and 100mg doses, in relation to that of other FDA-approved stimulant medications."

Dr. Bev Incledon, EVP, Research & Development for Ironshore Pharmaceuticals & Development, Inc. added, "Head-to-head studies assessing safety and efficacy of Jornay PM and other stimulants have not been conducted and Jornay PM is not substitutable with other methylphenidate products on a milligram per milligram basis. In this analysis, a 100-mg dose of JORNAY PM produces a maximum serum methylphenidate concentration that is either equal to or lower than that of 54mg and 60mg of other methylphenidate products. While this may surprise some healthcare professionals, this result is directly attributable to the site of absorption for Jornay PM, the colon, which has vastly different absorption qualities relative to the stomach and upper intestine. Although the Cmax was proportionately lower than expected, the absorption window was significantly longer. Together, this resulted in 74% bioavailability relative to a Ritalin IR comparator."

JORNAY PM is the first and only stimulant medication that is dosed in the evening and has demonstrated improved ADHD symptom control in the early morning, throughout the day and during the evening time period in two pivotal Phase 3 trials.

WARNING: ABUSE AND DEPENDENCE

See full prescribing information for complete boxed warning.

See additional important safety information below.

JORNAY PM is the first product to leverage the novel DELEXIS delayed-release and extended-release drug delivery technology that contains two functional film coatings. The first layer delays the initial release of drug for up to 10 hours while the second layer helps to control the rate of release of the active pharmaceutical ingredient from the time the patient awakens the next morning, throughout the day and into the evening.

About ADHDADHD is among the most common childhood psychiatric conditions with behavioral symptoms fluctuating throughout the day. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors, or be overly active. Many home-based difficulties for children and adolescents with ADHD occur during the early morning routine (i.e., before the school day begins).

Story continues

About JORNAY PMDeveloped by Ironshore Pharmaceuticals & Development, Inc., JORNAY PM is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people six years of age and older. JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity in people six years of age and older with ADHD. It is not known if JORNAY PM is safe and effective in children under six years of age.

JORNAY PM is dosed once daily in the evening and should be initiated at 8:00 p.m. Timing of administration of JORNAY PM may be adjusted between 6:30 p.m. and 9:30 p.m. to optimize the tolerability and the efficacy the next morning and throughout the day. The recommended starting dose for patients 6 years and older is 20 mg once daily in the evening. Dosage may be titrated weekly in increments of 20 mg per day up to maximum daily dose of 100 mg. The mean optimized dose required to improve symptoms from the time the patient wakes up, throughout the day and into the evening in children 6-12 years old was 67 mg in Study 1 and 68.1 mg in Study 2. The relative bioavailability of JORNAY PM (given once a day) compared to the same daily dose of a methylphenidate immediate-release oral product (given 3 times a day) in adults is approximately 74%. JORNAY PM is primarily absorbed in the colon which may contribute to the reduced bioavailability of the drug. JORNAY PM is not interchangeable on a milligram-per-milligram basis with other methylphenidate formulations.

Please see additional dosing information in the full prescribing information for JORNAY PM at http://ironshorepharma.com/labeling.pdf.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCECNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

PREGNANCY AND LACTATION

Please visit http://ironshorepharma.com/labeling.pdf for additional important safety information and the Full Prescribing Information, including Boxed Warning, for JORNAY PM.

About Ironshore Pharmaceuticals Inc.Ironshore Pharmaceuticals Inc. commercializes innovative, patient-centric treatment options to improve the lives of patients and caregivers. Based in North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US. Ironshore Pharmaceuticals Inc. is a wholly owned subsidiary of Highland Therapeutics Inc. based in Toronto, Canada.

About Ironshore Pharmaceuticals & Development, Inc.Ironshore Pharmaceuticals & Development, Inc., based in Grand Cayman, develops novel therapeutics by leveraging its proprietary drug-delivery technology, DELEXIS. Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Highland Therapeutics Inc. based in Toronto, Canada.

Forward-Looking StatementsThis press release contains forward-looking information, which reflects Ironshores current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Ironshores control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Ironshore assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005104/en/

Contacts

Lora GrassilliKovak-Likly Communications(203) 762-8833lgrassilli@klcpr.com

Read the original post:
Ironshore to Present Posters at the 2020 Neuroscience Education Institute Virtual Scientific Poster Session - Yahoo Finance

Aaron, Autry, Shinohara Honored with the Binswanger Prize for Excellence in Teaching – Wesleyan Connection

Every spring, Wesleyan recognizes outstanding faculty with three Binswanger Prizes for Excellence in Teaching.

This years recipients include Gloster Aaron, associate professor of biology, Robyn Autry, associate professor and chair of sociology, and Keiji Shinohara, artist-in-residence.

Made possible by gifts from the family of the late Frank G. Binswanger Sr., Hon. 85, these prizes underscore Wesleyans commitment to its scholar-teachers, who are responsible for the Universitys distinctive approach to liberal arts education.

Recommendations are solicited from alumni of the last 10 graduating classes, as well as current juniors, seniors, and graduate students. Recipients are chosen by a selection committee of faculty and members of the Alumni Association Executive Committee.

The Binswanger awards will be presented in person on a future occasion. The recipients and their bios are below:

Gloster Aaron

Gloster Aaron, associate professor of biology, joined the Wesleyan faculty in January 2006. He holds a BA in Neuroscience from Oberlin College and a PhD in Neuroscience from the University of Pennsylvania. Aarons lab pursues research projects related to the understanding, prevention, and treatment of epilepsy, using optical and electrophysiological methods of measuring neuronal activity. His research has included testing whether stem cell-derived, GABAergic neurons that are transplanted into adult brains can functionally integrate into hippocampal circuits and provide seizure-preventing inhibition. In related projects, he is also studying how newly-born neurons develop and are incorporated in adult brain circuits. With regards to epilepsy, he studies the dynamics of seizures that are functionally connected by the corpus callosum, the main white matter tract connecting the two cerebral cortices of the brain. This project seeks to explain the role GABAergic inhibition plays in the propagation of these seizures between hemispheres.

At Wesleyan, Aaron teaches courses in Behavioral Neurobiology; Waves, Brains, and Music; and Neurophysiology, among others. He is the director of WesMaSS, an academic program designed to support students from traditionally underrepresented groups as they pursue studies in mathematics and science.

Robin Autry

Robyn Autry, associate professor and chair of sociology, has been a member of Wesleyans faculty since 2010. She is a writer and critical sociologist with broad interests in racial identity, memory, and blackness. Her academic writing on commemorative practices around racial violence in the United States and South Africa has appeared in several journals, includingVisual StudiesandTheory & Society.Her public writing has appeared inTheAtlanticandBlack Perspectives. She is the author ofDesegregating the Past: The Public Life of Memory in the United States and South Africa (2017).Her second book,Selfishly Black, is currently under review.

She is the recipient of the Andrew W. Mellon Public Humanities Fellowship at the University of Toronto for the 202021 academic year. At Wesleyan, she teaches a range of courses including Social Analysis; Race, Fantasy, Fetish; and The Hair Class.

Keiji Shinohara

Keiji Shinohara, artist-in-residence, has taught at Wesleyan since 1995. Born and raised in Osaka, Japan, he studied as an apprentice to the renowned Keiichiro Uesugi in Kyoto for a decade before becoming a Master Printmaker. Shinoharas natural abstractions are printed on rice paper with water-based inks from woodblocks in the Ukiyo-e style.

Shinohara has been a visiting artist at over 100 venues, and has received grants from the Japan Foundation and the National Endowment for the Arts. His work is featured in many public collections, including the Fine Arts Museum of San Francisco, the Cleveland Museum of Art, the Milwaukee Art Museum, the Fogg Art Museum at Harvard University, and the Library of Congress. He has given lectures at the Los Angeles County Museum of Art, Museum of Fine Arts Boston, Metropolitan Museum of Art, and the Smithsonian Institution, among others. At Wesleyan, he teaches courses including Intro to Sumi-e Painting, Monotype Printmaking, and Alternative Printmaking: Beginning Japanese Woodblock Technique.

Read the original:
Aaron, Autry, Shinohara Honored with the Binswanger Prize for Excellence in Teaching - Wesleyan Connection

PDE Inhibitors Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| 3w Market News Reports – 3rd Watch News

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global PDE Inhibitors market. It informs readers about key trends and opportunities in the global PDE Inhibitors market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global PDE Inhibitors market.

Key companies operating in the global PDE Inhibitors market include Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, AstraZeneca, Bayer, Celgene, Eli Lilly, Pfizer, BioCrea, Dart NeuroScience, Carinopharm, CTC Bio, FORUM Pharmaceuticals, Intra-Cellular Therapies, Omeros Corporation, Medimetriks Pharmaceuticals, NuSirt Biopharma, Palobiopharma, Roivant Sciences, Sagene Pharmaceuticals, Tetra Discovery Partners, Tritech Biopharm, Otsuka, Chiesi Farmaceutici, Verona Pharma, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1762608/covid-19-impact-on-pde-inhibitors-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global PDE Inhibitors market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global PDE Inhibitors Market Segment By Type:

,PDE5,PDE4,Viagra,Cialis,Levitra,Others

Global PDE Inhibitors Market Segment By Application:

,Genitourinary,Cardiovascular Diseases,Dermatological Disorders,Respiratory Diseases,Schizophrenia,AlzheimerS Disease,HuntingtonS Disease,Others

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global PDE Inhibitors market.

Key companies operating in the global PDE Inhibitors market include Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, AstraZeneca, Bayer, Celgene, Eli Lilly, Pfizer, BioCrea, Dart NeuroScience, Carinopharm, CTC Bio, FORUM Pharmaceuticals, Intra-Cellular Therapies, Omeros Corporation, Medimetriks Pharmaceuticals, NuSirt Biopharma, Palobiopharma, Roivant Sciences, Sagene Pharmaceuticals, Tetra Discovery Partners, Tritech Biopharm, Otsuka, Chiesi Farmaceutici, Verona Pharma, etc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1762608/covid-19-impact-on-pde-inhibitors-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on PDE Inhibitors Industry1.7 COVID-19 Impact: PDE Inhibitors Market Trends 2 Global PDE Inhibitors Quarterly Market Size Analysis2.1 PDE Inhibitors Business Impact Assessment COVID-192.1.1 Global PDE Inhibitors Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global PDE Inhibitors Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global PDE Inhibitors Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 Global PDE Inhibitors Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global PDE Inhibitors Factory Price by Manufacturers3.3 Location of Key Manufacturers PDE Inhibitors Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into PDE Inhibitors Market3.5 Key Manufacturers PDE Inhibitors Product Offered3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on PDE Inhibitors Segments, By Type4.1 Introduction1.4.1 PDE51.4.2 PDE41.4.3 Viagra1.4.4 Cialis1.4.5 Levitra1.4.6 Others4.2 By Type, Global PDE Inhibitors Market Size, 2019-20214.2.1 By Type, Global PDE Inhibitors Market Size by Type, 2020-20214.2.2 By Type, Global PDE Inhibitors Price, 2020-2021 5 Impact of Covid-19 on PDE Inhibitors Segments, By Application5.1 Overview5.5.1 Genitourinary5.5.2 Cardiovascular Diseases5.5.3 Dermatological Disorders5.5.4 Respiratory Diseases5.5.5 Schizophrenia5.5.6 AlzheimerS Disease5.5.7 HuntingtonS Disease5.5.8 Others5.2 By Application, Global PDE Inhibitors Market Size, 2019-20215.2.1 By Application, Global PDE Inhibitors Market Size by Application, 2019-20215.2.2 By Application, Global PDE Inhibitors Price, 2020-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Hanmi Science Holding7.1.1 Hanmi Science Holding Business Overview7.1.2 Hanmi Science Holding PDE Inhibitors Quarterly Production and Revenue, 20207.1.3 Hanmi Science Holding PDE Inhibitors Product Introduction7.1.4 Hanmi Science Holding Response to COVID-19 and Related Developments7.2 Boehringer Ingelheim7.2.1 Boehringer Ingelheim Business Overview7.2.2 Boehringer Ingelheim PDE Inhibitors Quarterly Production and Revenue, 20207.2.3 Boehringer Ingelheim PDE Inhibitors Product Introduction7.2.4 Boehringer Ingelheim Response to COVID-19 and Related Developments7.3 Takeda Pharmaceuticals7.3.1 Takeda Pharmaceuticals Business Overview7.3.2 Takeda Pharmaceuticals PDE Inhibitors Quarterly Production and Revenue, 20207.3.3 Takeda Pharmaceuticals PDE Inhibitors Product Introduction7.3.4 Takeda Pharmaceuticals Response to COVID-19 and Related Developments7.4 AstraZeneca7.4.1 AstraZeneca Business Overview7.4.2 AstraZeneca PDE Inhibitors Quarterly Production and Revenue, 20207.4.3 AstraZeneca PDE Inhibitors Product Introduction7.4.4 AstraZeneca Response to COVID-19 and Related Developments7.5 Bayer7.5.1 Bayer Business Overview7.5.2 Bayer PDE Inhibitors Quarterly Production and Revenue, 20207.5.3 Bayer PDE Inhibitors Product Introduction7.5.4 Bayer Response to COVID-19 and Related Developments7.6 Celgene7.6.1 Celgene Business Overview7.6.2 Celgene PDE Inhibitors Quarterly Production and Revenue, 20207.6.3 Celgene PDE Inhibitors Product Introduction7.6.4 Celgene Response to COVID-19 and Related Developments7.7 Eli Lilly7.7.1 Eli Lilly Business Overview7.7.2 Eli Lilly PDE Inhibitors Quarterly Production and Revenue, 20207.7.3 Eli Lilly PDE Inhibitors Product Introduction7.7.4 Eli Lilly Response to COVID-19 and Related Developments7.8 Pfizer7.8.1 Pfizer Business Overview7.8.2 Pfizer PDE Inhibitors Quarterly Production and Revenue, 20207.8.3 Pfizer PDE Inhibitors Product Introduction7.8.4 Pfizer Response to COVID-19 and Related Developments7.9 BioCrea7.9.1 BioCrea Business Overview7.9.2 BioCrea PDE Inhibitors Quarterly Production and Revenue, 20207.9.3 BioCrea PDE Inhibitors Product Introduction7.9.4 BioCrea Response to COVID-19 and Related Developments7.10 Dart NeuroScience7.10.1 Dart NeuroScience Business Overview7.10.2 Dart NeuroScience PDE Inhibitors Quarterly Production and Revenue, 20207.10.3 Dart NeuroScience PDE Inhibitors Product Introduction7.10.4 Dart NeuroScience Response to COVID-19 and Related Developments7.11 Carinopharm7.11.1 Carinopharm Business Overview7.11.2 Carinopharm PDE Inhibitors Quarterly Production and Revenue, 20207.11.3 Carinopharm PDE Inhibitors Product Introduction7.11.4 Carinopharm Response to COVID-19 and Related Developments7.12 CTC Bio7.12.1 CTC Bio Business Overview7.12.2 CTC Bio PDE Inhibitors Quarterly Production and Revenue, 20207.12.3 CTC Bio PDE Inhibitors Product Introduction7.12.4 CTC Bio Response to COVID-19 and Related Developments7.13 FORUM Pharmaceuticals7.13.1 FORUM Pharmaceuticals Business Overview7.13.2 FORUM Pharmaceuticals PDE Inhibitors Quarterly Production and Revenue, 20207.13.3 FORUM Pharmaceuticals PDE Inhibitors Product Introduction7.13.4 FORUM Pharmaceuticals Response to COVID-19 and Related Developments7.14 Intra-Cellular Therapies7.14.1 Intra-Cellular Therapies Business Overview7.14.2 Intra-Cellular Therapies PDE Inhibitors Quarterly Production and Revenue, 20207.14.3 Intra-Cellular Therapies PDE Inhibitors Product Introduction7.14.4 Intra-Cellular Therapies Response to COVID-19 and Related Developments7.15 Omeros Corporation7.15.1 Omeros Corporation Business Overview7.15.2 Omeros Corporation PDE Inhibitors Quarterly Production and Revenue, 20207.15.3 Omeros Corporation PDE Inhibitors Product Introduction7.15.4 Omeros Corporation Response to COVID-19 and Related Developments7.16 Medimetriks Pharmaceuticals7.16.1 Medimetriks Pharmaceuticals Business Overview7.16.2 Medimetriks Pharmaceuticals PDE Inhibitors Quarterly Production and Revenue, 20207.16.3 Medimetriks Pharmaceuticals PDE Inhibitors Product Introduction7.16.4 Medimetriks Pharmaceuticals Response to COVID-19 and Related Developments7.17 NuSirt Biopharma7.17.1 NuSirt Biopharma Business Overview7.17.2 NuSirt Biopharma PDE Inhibitors Quarterly Production and Revenue, 20207.17.3 NuSirt Biopharma PDE Inhibitors Product Introduction7.17.4 NuSirt Biopharma Response to COVID-19 and Related Developments7.18 Palobiopharma7.18.1 Palobiopharma Business Overview7.18.2 Palobiopharma PDE Inhibitors Quarterly Production and Revenue, 20207.18.3 Palobiopharma PDE Inhibitors Product Introduction7.18.4 Palobiopharma Response to COVID-19 and Related Developments7.19 Roivant Sciences7.19.1 Roivant Sciences Business Overview7.19.2 Roivant Sciences PDE Inhibitors Quarterly Production and Revenue, 20207.19.3 Roivant Sciences PDE Inhibitors Product Introduction7.19.4 Roivant Sciences Response to COVID-19 and Related Developments7.20 Sagene Pharmaceuticals7.20.1 Sagene Pharmaceuticals Business Overview7.20.2 Sagene Pharmaceuticals PDE Inhibitors Quarterly Production and Revenue, 20207.20.3 Sagene Pharmaceuticals PDE Inhibitors Product Introduction7.20.4 Sagene Pharmaceuticals Response to COVID-19 and Related Developments7.21 Tetra Discovery Partners7.21.1 Tetra Discovery Partners Business Overview7.21.2 Tetra Discovery Partners PDE Inhibitors Quarterly Production and Revenue, 20207.21.3 Tetra Discovery Partners PDE Inhibitors Product Introduction7.21.4 Tetra Discovery Partners Response to COVID-19 and Related Developments7.22 Tritech Biopharm7.22.1 Tritech Biopharm Business Overview7.22.2 Tritech Biopharm PDE Inhibitors Quarterly Production and Revenue, 20207.22.3 Tritech Biopharm PDE Inhibitors Product Introduction7.22.4 Tritech Biopharm Response to COVID-19 and Related Developments7.23 Otsuka7.23.1 Otsuka Business Overview7.23.2 Otsuka PDE Inhibitors Quarterly Production and Revenue, 20207.23.3 Otsuka PDE Inhibitors Product Introduction7.23.4 Otsuka Response to COVID-19 and Related Developments7.24 Chiesi Farmaceutici7.24.1 Chiesi Farmaceutici Business Overview7.24.2 Chiesi Farmaceutici PDE Inhibitors Quarterly Production and Revenue, 20207.24.3 Chiesi Farmaceutici PDE Inhibitors Product Introduction7.24.4 Chiesi Farmaceutici Response to COVID-19 and Related Developments7.25 Verona Pharma7.25.1 Verona Pharma Business Overview7.25.2 Verona Pharma PDE Inhibitors Quarterly Production and Revenue, 20207.25.3 Verona Pharma PDE Inhibitors Product Introduction7.25.4 Verona Pharma Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis8.1 PDE Inhibitors Supply Chain Analysis8.1.1 PDE Inhibitors Supply Chain Analysis8.1.2 Covid-19 Impact on PDE Inhibitors Supply Chain8.2 Distribution Channels Analysis8.2.1 PDE Inhibitors Distribution Channels8.2.2 Covid-19 Impact on PDE Inhibitors Distribution Channels8.2.3 PDE Inhibitors Distributors8.3 PDE Inhibitors Customers 9 Key Findings 10 Appendix10.1 About Us10.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
PDE Inhibitors Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| 3w Market News Reports - 3rd Watch News

Researchers Created a 3-D Map of 100 Million Cells in the Mouse Brain – Smithsonian.com

Researchers at the Allen Institute for Brain Science have accomplished a feat of cartography, creating a map of a standard mouse brain with details down to the cellular level.

The results, published on May 7 in the journal Cell, provide a 3-D atlas of an average mouses brain structure as a reference for neuroscientists everywhere. The new map is the third iteration of the project, and shows details with a new level of granularity, including over 800 brain structures and 100 million individual cells.

We hope the wider neuroscience community will use it as a new standard reference atlas, Allen Institute neuroscientist and co-author Lydia Ng tells James Lloyd at the BBCs Science Focus.

Researchers can reference the 3-D map of the mouse brain to better understand which brain regions are activated during an experiment. Different structures in the brain have certain tasks. In humans, the fusiform area can spot a face, the amygdala is the fear center, and longtime players of the Pokmon franchise may even have a region committed to recognizing the games characters. The mouse brain atlas is the based on over 1,600 mouse brains, creating a standard template that clearly delineates hundreds of structures.

Weve created this really beautiful average mouse brain, co-author David Feng told Spectrums Hannah Furfaro when the map was first presented at the Society for Neuroscience annual meeting in 2017. What you see remaining after all the averaging we do is very sharp definitions of structures that are stereotypical, which means theres not a lot of wiggle room anymore.

Neuroscientists can then use the atlas to understand where exactly theyre seeing activity in their own experiments in mice. Scientists used to eyeball the region that a blip on a measurement tool was coming from, but as modern experiments collect an increasing amount of data, a digital tool for pinpointing a signals source became vital, Ng says in a statement. Researchers can also use the average brain model to compare the shape of the brain with mice that are bred to have conditions that affect the brain.

As Ryan Blethen reported for the Seattle Times last August, researchers at the Allen Institute are also working on projects clarifying the things that our brains have in common with mouse brains, and highlighting the differences. And in October, the institute announced the completion of a map of how the mouse brain is wired. The tools are all available online for ease of access in the neuroscience field.

By making our atlas and related tools open access, new data and data types generated across our community can be more easily integrated and compared in the same spatial context, Ng tells Science Focus, and the atlas in turn can be modified as our knowledge about brain structure evolves.

Because the tool was first released online in 2017, its already been used to complete some research. University of Washington neuroscientist Nick Steinmetz used the mouse brain atlas to analyze data from a project aimed at understanding how mice choose between images. The study, published in Nature in November, used the tool to understand where exactly the brain was active.

The atlas was a really necessary resource that enabled the very idea of doing studies at the brain-wide level, Steinmetz, who wasnt involved with the new study but is associated with the Allen Institute, said in a statement. When youre recording from hundreds of sites across the brain, that introduces a new scale of investigation. You have to have a bigger view of where all the recording sites are, and the CCF [mouse brain map] is what made that possible.

Like this article?SIGN UP for our newsletter

View original post here:
Researchers Created a 3-D Map of 100 Million Cells in the Mouse Brain - Smithsonian.com

DePauw graduates 472 seniors in virtual ceremony shown around the world – DePauw University

May 17, 2020

DePauw University conferred degrees today on 472 graduating seniors in a virtual ceremony streamed on YouTube.

The virtual ceremony, necessitated by the COVID-19 pandemic, will be followed by an in-person ceremony being planned for a later date. Members of the Class of 2020 voted for the dual recognitions, and DePauw wanted to ensure that degrees had been officially conferred on students whose next plans to attend graduate school or go into the military require such official action.

DePauw has a sizeable enrollment of international students, so a worldwide audience was looking on as President D. Mark McCoy told the graduates, you have done the difficult work with necessary fortitude: You have attended the classes, put in long hours of study, met with your professors and advisers and even learned how to do all of these things remotely doing anything and everything necessary to fulfill the requirements for your degrees.

You have earned the right to mark your triumphs and to celebrate your achievements.

Tim Good, the professor of communication and theatre chosen by class members to speak, said, what I have to say to you, what I am not ashamed to say, is that your teachers love you.And of course, I mean faculty, but I also mean staff members. I mean food service, laboratory assistants, administrative assistants, coaches.I meancustodians, facilities, student life and many, many others.I also mean administrators, trustees, alumni. And I really mean it. Were all here for you.

Two students were honored with the most prestigious awards DePauw gives to graduating seniors.

Brittany Davis received the Walker Cup Award, given to the member of the graduating class who has been determined to have contributed the most to the university during his or her four years of enrollment.

Upon starting my DePauw journey four years ago, I had no idea that I would be able to grow so much, both inside and outside of the classroom, said Davis, who plans to pursue an M.D.-Ph.D. program toward becoming a medical research physician. The experiences I have had have been truly incredible and have sculpted me into who I am today.

Davis, a Holton scholar from Indianapolis, double majored in neuroscience and global health and minored in Spanish and chemistry. She was a science research fellow and an information technology associate who conducted and presented several STEM research projects at major conferences; worked as a research intern for Massachusetts General Hospital for Children and Harvard Medical School; and studied and conducted research in India, Sri Lanka, South Africa, Japan and Cuba.

She was the founding member of the Students of Color in STEM organization; chartered a Minority Association of Pre-Medical Students chapter at DePauw; and worked as a mentor and a tutor in the Greencastle community as a member of Alpha Kappa Alpha Sorority Inc.

The other nominees for the Walker Cup were Luka Ignac, Summer Pappachen and Brenda Rodriguez.

Ignac, who majored in political science and French and minored in peace and conflict studies, was awarded the Murad Medal, which recognizes the senior who has had the most significant scholarly and/or artistic achievements during his or her time at DePauw.

The medal is named for Ferid Murad 58, a physician and Ph.D. pharmacologist who won the Nobel Prize for his far-reaching contributions to medical science.

Ignac, a native of Croatia, plans to attend Georgetown Universitys Master of German and European Affairs program as one of five global public service leaders to receive a prestigious McHenry Fellowship.

While a DePauw student, he investigated NATOs role in transatlantic crises, which resulted in an invitation to conduct a policy workshop during the 2019 European Conference at the Harvard Kennedy School. He served as a political affairs intern at the Embassy of the Republic of Croatia to the United States and he studied in Belgium, where he conducted comparative research on the security policies of the European Union and NATO.

He worked as an intern at DePauws Prindle Institute for Ethics, during which time he served as the president of the DePauw chapter of European Horizons, a transatlantic youth think tank based at Yale University, and coauthored several policy papers about cybersecurity, cybercrime and the consequences of Brexit for transatlantic relations.

Ignac also was selected to Phi Beta Kappa, the countrys most prestigious honor society, and Pi Sigma Alpha, the honor society for undergraduate and graduate political science students. He previously received the Richard Bunch Award for Best Junior in Political Science; the Ambassador Viron P. Vaky Award for Inter-American Relations; and the Vera Scholarship for International Students.

Other finalists for the Murad Medal were John Cotton and Zachary Wilkerson.

A video of the ceremony will be available for viewing afterward.

The rest is here:
DePauw graduates 472 seniors in virtual ceremony shown around the world - DePauw University

Anatomy of a Killer: What the Coronavirus Does Inside the Body – DER SPIEGEL

The pathogen has already done a fair bit of damage. It has only been five days since the patient began exhibiting typical COVID-19 symptoms, but already, menacing shadows can be seen in the CT scans of the lungs.

"It's like frosted glass," is how Christian Strassburg, a professor of internal medicine at the Bonn University Hospital, describes the changes made visible by the scan. "The lung tissue is saturated with fluid." Secretions and dead cells are gumming up the walls of the pulmonary alveoli "like Jell-O," he says.

"It is extremely difficult for oxygen to permeate a layer like that to get from the lung into the bloodstream," the professor explains. It is a phenomenon he has been seeing frequently in recent weeks and it is caused by the novel coronavirus, SARS-CoV-2. The number of confirmed COVID-19 patients worldwide is now well over 4.2 million and the number of deaths is approaching 300,000. Meanwhile, doctors and biologists are doing all they can to gain a better understanding of the pathogen behind the pandemic.

SARS-CoV-2 behaves differently than almost any other virus that humans have faced before, and even now, several months into the pandemic, there is disagreement as to what percent of COVID-19 patients experience severe symptoms. Estimates tend to come in at around 5 percent of all infections. And in those cases, the virus unfolds unfathomable destructive power.

cgs

The article you are reading originally appeared in German in issue 20/2020 (May 09, 2020) of DER SPIEGEL.

The epicenter of such infections is almost always the lungs. But as medical professionals now realize, the virus can also affect other organs and tissues - including the heart, the brain, the kidneys and the bowels. In the worst case, the body begins attacking itself. When the immune system spins out of control like that, doctors call it a "cytokine storm," and when patients die as a result, multiple organ failure tends to be the cause.

Over 100 vaccine candidates are currently being developed worldwide to combat SARS-CoV-2, but in the worst-case scenario, it could take years before a vaccine is available. Until it is, the virus will still be with us. Even if the pandemic does weaken a bit, experts believe a second wave is just around the corner.

Early talk of COVID-19 as being mostly a mild illness has been proven to be "dangerously false," Richard Horton, editor-in-chief of the medical journal The Lancet, has written. At the bedside, he says, it is "a story of terrible suffering, distress and utter bewilderment." U.S. cardiologist Harlan Krumholz described the ferocity of COVID-19 in the magazine Science as "breathtaking and humbling." The disease, he continued, "can attack almost anything in the body with devastating consequences."

The best way to learn more about SARS-CoV-2 is to start small. Coronaviruses are a mere 160 nanometers in size. In order to multiply, the tiny pathogens are reliant on the cells belonging to a different organism.

The novel coronavirus likely comes from bat viruses, and it is thought that, even before it made the jump to humans, it developed the mechanism allowing it to bind with human cells. Some bat viruses are able to bind to a receptor called ACE2. This molecule can be found on the surface of human cells and helps regulate blood pressure. But it also functions as a kind of doorway to the interstices of the cell, and viruses that have the key can get inside.

Researchers believe that bats carry around 3,200 different coronaviruses. Chance, time and opportunity fueled the creations of the SARS-CoV-2 virus, which ultimately managed to jump to humans.

But how exactly does the virus find its way into the human body? Internal medicine professor Strassburg is quite familiar with the process. At the Bonn University Hospital, he is currently in charge of between 10 and 20 COVID-19 patients. On one day recently, eight of them were intubated, having become so ill that they were forced to rely on ventilators. "Luckily, that is the minority," Strassburg says. "Most of those infected by the virus get away with only mild symptoms."

Early on, virologists thought that the novel coronavirus would spread only slowly, in part due to the similarities between SARS-CoV-2 and the SARS coronavirus that appeared in China in 2002. From November 2002 and July 2003, almost 800 people died of the disease, the full name of which is Severe Acute Respiratory Syndrome. But then, the epidemic disappeared. It was a stroke of luck for humanity: That pathogen appears to have been more deadly than SARS-CoV-2, but it focused its attentions on the lungs. The virus multiplied deep within the body, making it less contagious. Furthermore, it was easy to identify and isolate those who had fallen ill from the virus.

Experts initially hoped that the same would hold true of SARS-CoV-2, but they were mistaken. The novel coronavirus doesn't just attack the lungs. Throat swabs from patients revealed early on that the pathogen first goes after the mucous membrane in the upper respiratory tract.

That is advantageous for the virus. The distance from one throat to another throat is much shorter than the distance from one person's lung to another. "That means that those carrying the virus are highly contagious," says Strassburg. A huge number of the viruses are found in the nasal cavity and pharynx, "even in people who aren't yet experiencing symptoms," he adds, "which is why the pathogen was able to circle the globe so quickly."

There are three stages in the attack on the human body. Initially, the coronavirus binds with club-shaped protein complexes on the ACE2 receptors of human cells. That opens up the host cell and allows genetic material from the pathogen to enter. The virus then converts the cell into a virus factory. Huge numbers of viruses thus produced then leave the host cell and attack other cells.

The SARS-CoV-2 Virus focuses its attack on the lungs. The delicate alveoli are most at risk.

The resulting viral load is enormous, particularly in the first week following infection. And initially, there are hardly any symptoms. Often, there is merely a dry cough, says Strassburg, with the body's temperature hardly rising at all. "Even patients who are more severely affected generally have a temperature below 38 degrees Celsius (100.4 degrees Fahrenheit)." That is a significant difference to the flu: "For influenza, a sudden rise in temperature is typical, along with a distinctive feeling of being sick. But that's not the case here."

In this initial phase of the illness, much depends on the patient's immune system. Immune cells attack the invaders, but because the body isn't yet familiar with the virus, the weapons at their disposal are relatively basic.

A battle of attrition ensues, one that determines whether the patient will quickly recover or whether the disease will get the upper hand. Will the immune system stop the attack in the upper respiratory tract? Or will the pathogen be able to find its way into the lungs? The answers to those questions determine whether the illness becomes life threatening or not.

Researchers are still trying to figure out why the virus is able to reach the lungs of some patients but is stopped short in others. One of the factors appears to be the number of pathogens that attack the body at the beginning. More than anything, though, patients with underlying medical conditions seem to have the most to fear from SARS-CoV-2. According to estimates, about a quarter of the population in Central Europe has such an underlying condition.

Those at risk include people suffering from obesity, diabetes and high blood pressure. And smokers: "Their mucous membranes and lung ventilation are already impaired," says Strassburg. Tiny hair-like projections known as cilia, which normally help keep pathogens and mucous out of the lungs and respiratory tract, no longer function appropriately.

In such cases, there are hardly any hurdles for the virus on the way to the lungs. Gravity is sufficient for the tiny pathogens to reach their target. Once the virus advances into the smaller, branch-like bronchioles, it meets a particularly vulnerable layer of cells, the membranes of which are also covered with ACE2 receptors. Directly in the pulmonary alveoli, the tiny sacs where oxygen is transferred into the bloodstream, SARS-CoV-2 finds perfect conditions.

To depict the precise damage the virus does in the lungs, thoracic surgeon Keith Mortman of George Washington University Hospital in Washington, D.C., turned to computer modelling. The 3-D imagery from the clinic shows the lungs of a man in his late 50s. Yellow-tinged deposits can be seen in many areas within the organ.

"The damage we are seeing is not isolated to any one part of the lung," says Mortman. Initially, he says, the patient experienced a fever and a cough, before then developing serious breathing difficulties. He was intubated and attached to a ventilator, but when that proved insufficient, he was hooked up to a so-called ECMO machine.

The machine infuses blood with oxygen outside of the body before pumping it back inside. The hope is that the procedure will give the lungs the time they need to recover.

Doctors now have a deeper understanding of how SARS-CoV-2 damages lung tissue. White blood cells discover the virus and attract other immune cells to the site, which attack the infected lung cells and kill them. They leave behind cell detritus, which clog up the alveoli. If the body isn't able to gain control over the reaction to the infection, acute lung failure looms.

But other organs can also be damaged as a result of the infection. The more SARS-CoV-2 patients are treated around the world, the clearer it has become just how comprehensive the attack staged by the virus is.

According to data from China, around 20 percent of patients requiring hospitalization suffer damage to the heart. It remains unclear whether the virus goes after heart muscle cells directly or if damage to the coronary blood vessels is to blame. The blood clotting function is also disrupted, leading to clumps that could result in heart attacks, lung embolisms and strokes.

The kidneys of some hospitalized patients also come under attack, as evidenced by blood or protein in urine samples. As a result, dialysis machines have had to join ventilators in ICUs devoted to treating COVID-19 patients.

Doctors have likewise observed brain inflammation and seizures in some patients. The virus apparently advances all the way into the brain stem, where important control centers are located, such as the one responsible for breathing. The virus likely gets to the brain via the mucous membrane inside the nose and the olfactory nerve. This could also be the reason that many patients temporarily lose their sense of smell.

SARS-CoV-2 can also attack the digestive tract, with patients complaining of bloody diarrhea, nausea and abdominal pain.

Doctors have also reported a possible link between COVID-19 and a rare blood vessel syndrome in children called Kawasaki Disease. In Britain, the disease has even killed a few children who became infected with SARS-CoV-2. The disease involves the inflammation of blood vessels throughout the body and can damage the heart.

Doctors now believe that SARS-CoV-2 attacks tissue and organs virtually everywhere in the body. And the disease can also apparently leave behind long-term damage. Chinese researchers have examined the blood of patients and found that even after the infection has passed, certain blood values remain abnormal for an extended period. Despite the virus no longer being present in the body, for example, their livers still don't exhibit normal functionality.

The virus can make it all the way into the brain, triggering seizures and inflammation.

The lungs, too, likely suffer lasting damage in severe cases. "When inflammation does not subside with time, then it becomes essentially scarring in the lungs, creating long-term damage," says Mortman, the doctor from George Washington University Hospital.

It is still too early for a comprehensive understanding of the long-term consequences of COVID-19. But doctors are familiar with cytokine storms and acute lung failure from other severe infections. Some of the survivors of the first SARS epidemic, for example, experienced limited lung functionality for up to 15 years after the illness.

But why do some people emerge virtually unscathed from this multifaceted attack while others do not? Thus far, researchers do not have an answer to this question. There are indications that the virus - similar to the pathogen that causes AIDS is able to attack certain white blood cells, thus damaging precisely that line of defense that is supposed to stop the infection.

Are some patients more susceptible than others to that phenomenon for genetic reasons? The biotechnology company 23andMe intends to comb through the DNA of its 10 million customers in the search for sequences that could be predictive of their susceptibility to severe COVID-19.

Until the question is answered for sure, however, most patients can continue to rely on hope. After all, most people do not experience severe symptoms from the disease. "Among patients without underlying conditions, even severe cases have an 80 percent survival rate," estimates Christian Strassburg, the internal medicine specialist. Still, it is by no means time to let down our guard, he says, particularly now that restrictions on public life are increasingly being lifted. "The danger remains extremely high that a large number of patients will soon have to be treated in hospitals."

That will heap even more pressure on doctors and nurses. The condition of some patients, after all, can worsen dramatically within just a few days.

Should death be the ultimate result, it is often not the virus itself that causes it, but the immune system of the infected patient, which can disastrously overreact and attack the body.

In such instances, huge numbers of so-called cytokines are released. These chemical signaling molecules produced by the body trigger a cascade of biochemical reactions that affect the immune system. The development of a fever accelerates the metabolism and helps kill the virus. Blood vessel walls are made more permeable, allowing easier access for immune cells, such as phagocytes, to attack the virus. The heartrate speeds up.

"The reaction is actually quite sensible," says Strassburg. But in cases of severe infection, the immune system can overreact and trigger a cytokine storm.

"The result is a reaction that looks like a massive blood infection, but isn't one," says Strassburg. It can lead, however, to multiple organ failure. "If the immune system overreaction to the pathogen continues for too long or is too severe, it will kill the body."

Vast destruction is the result, as pathologists can attest. Johannes Friedmann is a professor at Ldenscheid Hospital just south of Dortmund and has examined the bodies of several patients who succumbed to COVID-19. In the alveoli of these patients, he has found epithelial cells in the lung that have been "scaled off" in addition to protein "deposits" in the blood resulting from blood vessels that have become permeable. He has also discovered cells with multiple or enlarged nuclei, a phenomenon that is typical of viral illnesses.

The walls of the vast majority of the alveoli in the lungs are "widened to many times their normal thickness," Friemann says, adding that the lungs of many COVID-19 casualties are "insufficiently inflated." That impedes oxygen transfer.

Friemann's findings have been consistent with those of medical professionals in Hamburg, the United States, Switzerland and elsewhere: Most of those who died were sick before they came into contact with SARS-CoV-2. Friemann has found cases of liver cirrhosis, severe arterial sclerosis and extremely high blood pressure.

Did these patients die of SARS-CoV-2 or from other maladies? "You can't live with such a lung, so I would point to the virus as being the cause of death," says Friemann. "Many of these people would still be alive without the infection."

Indeed, a recent calculation by British epidemiologists casts significant doubt on claims that most COVID-19 victims would have died soon anyway. They found that female victims of the disease lose an average of 11 years of life. For men, the number was 13 years.

Go here to read the rest:
Anatomy of a Killer: What the Coronavirus Does Inside the Body - DER SPIEGEL

Attack on Titan Anatomy: 5 Weird Things About the Jaw Titan | CBR – CBR – Comic Book Resources

As one of the nine shifters, Ymir's Jaw Titan has a unique anatomy and in turn a unique set of skills in Attack on Titan.

At the end ofAttack on TitanSeason 2, the theory arose amongst the Scouts that titans were transformed humans, and this would later be confirmed in Season 3. Throughout the first two seasons there were clues to this, especially when Eren first transformed into the Attack Titan and when it was revealed Annie was another shifter; however, the biggest clue to this was with Ymir, a character who was a mystery from day one.

While other protagonists got some form of backstory, Ymir's was always kept in the dark, and for good reason. It wasn't until Season 2, Episode 4, "Soldier," that it was revealed she was another shifter, and shortly after, in Episode 5, "Historia," the audience learns she obtained this power by eating one of Bertholdt and Reiner's comrades, which turned her from a mindless titan into the shifter known as the Jaw Titan, who was originally sent alongside the Titan Trio to destroy the walls and obtain the Founding Titan. Like all shifters, the Jaw Titan has a unique anatomy compared to mindless titans, which gives her an advantage

RELATED: Attack on Titan Anatomy: 5 Weird Things About the Female Titan's Body

Upon first glance, the mostnotablething about this shifter is her size. Compared to all the other shifters introduced in the anime - the Attack Titan, the Colossal Titan, the Armored Titan, the Beast Titan, the Cart Titan and the Female Titan - she is the smallest, and she is even smaller than most mindless titans. This comes with advantages, which will be addressed later on, and disadvantages, such as being overpowered by larger titans, as seen in"Historia" when the mindless titansfinally outnumber her, toss her like a rag doll and devourpieces of Ymir.

Unlike the Colossal Titan or Rod Reiss's Titan, who both move ungodly slow due to their massive sizes, the Jaw Titan, thanks to her petite build, is one of the fastest shifters. Throughout second half of Season 2, audiences seeYmireasily catch up to Reiner'sArmored Titanand out run the scouts with their ODM gear. Even beforethe other characters know aboutthe Jaw Titan, Historia notices that Ymir is hiding something when she makes it down the mountain with Daz without any climbing gear and in record time. This should've taken an average person hours, and even for a titan it would've taken a while, but Ymir's Jaw Titan speeds down fast enough to save Daz from hypothermia.

Along with heightened agility, the Jaw Titan has more flexibility and dexterity than any other shifter. While the Armored Titan, Female Titan and Attack Titan have all displayed fighting capabilities, they do not have the same grace as the Jaw Titan, who can easily maneuver out of tight situations while also landing devastating blows. At Castle Utgard, fans see how effortlessly she can scale the tower, leap from titan to titan and hurl pieces of brick at her opponents, mimicking the grace of dancer or spider. Meanwhile, in the Giant Forest, Ymir swings like a monkey from branch to branch and preformas flips like an acrobat, which allows her to escape the Scouts.

RELATED: Attack on Titan Anatomy: 5 Weird Things About the Armored Titan

What helps with her acrobatics is her sharpened claws. While other shifters, like the Female Titan, have had touse their crystal abilities to make claws, the Jaw Titan naturally has a set of nails that can penetrate the hardest surfaces. With Castle Utgard, Ymir is able to hold onto a smooth surface thanks to her claws, and she is able pierce titanflesh with them, which is impressive when considering the fact that the Scouts had to develop specialized bladed to achieve the same feat.Similarly in the Giant Forest, Ymir can hang onto trees like the Scouts because her claws anchor her like their ODM gear does.

The biggest advantage of the Jaw Titan is her jaw, which is the strongest of the titan shifters. Where most shifters and mindless titans have teeth that resemble their human set, the Jaw Titan develops amouth fullof razor sharp fangs. Along with being sharp enough to easily penetrate the nape of titan's neck, this jaw can unhinge itself without the need of damaging the mouth, as the Female Titan has had to do. This makes the Jaw Titan'sanatomy similar to that of a snake as well as an alligator given the immense amount of strength the Jaw Titan can exert in a single bite, which makes this shifter incredibly dangerous.

KEEP READING: Attack on Titan Anatomy: 5 Weird Things About the Colossal Titan

The BLUE Hulk: How Banner's Cosmic Upgrade Made Him Even Stronger

After moving to New York, Caitlin Sinclair Chappell got a job at Forbidden Planet, a science fiction and comic book mega store, working as a sales associate and a writer for their newsletter, the Weekly Planet. Prior to moving across country, Caitlin was a honors student at Lewis & Clark College, where she was an editorial intern at Dark Horse Comics, a director on several short films, and a writer for the Odyssey and the Piolog - her articles focusing on comics, film, and theatre. With several friends from Portland, Caitlin co-started the Comic Book Buds podcast, which she still co-hosts to this day. In her free time, Caitlin volunteers for festivals and conventions like NewFest, Screamfest, and Wizard World. Shes currently working on a handful of creative projects, including her first comic and a two act play.

Read more:
Attack on Titan Anatomy: 5 Weird Things About the Jaw Titan | CBR - CBR - Comic Book Resources